News

Natural Molecule Slows Progression of Kidney Disease in Alport Mice

Exposing a mouse model of Alport syndrome to the naturally occurring factor pentraxin-2 slowed progression of kidney disease and increased mice lifespan, say researchers at the University of Washington in Seattle. Their findings, published in the journal JCI Insight, suggest that pentraxin-2 could potentially treat chronic fibrotic kidney disease. Speculating on…

Reata Tests Bardoxolone Methyl as Possible Treatment for Loss of Kidney Activity in Alport Syndrome

Reata Pharmaceuticals is investigating bardoxolone methyl as a potential treatment for chronic kidney disease (CKD) triggered by Alport syndrome. The CARDINAL (NCT03019185) Phase 2/3 clinical trial — which is currently recruiting patients — aims to determine the safety, tolerability and effectiveness of oral bardoxolone methyl in slowing, halting and possibly…